Federal Trade Commission Actions on Prescription Drugs, 2000-2022

This Special Communication examines the Federal Trade Commission’s policy and legal actions related to alleged misconduct, consolidation, and anticompetitive behavior in the pharmaceutical market between 2000 and 2022.